Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - WuXi AppTec Sells UK-US Units, but Annual Results Show Foreign Contracts Continue Despite China Tensions - ResearchAndMarkets.com

The "Bio/Pharmaceutical Outsourcing Report, March 2025" has been added to ResearchAndMarkets.com's offering.

The Bio/Pharmaceutical Outsourcing Report is an essential monthly resource that delves into the dynamic landscape of pharmaceutical Contract Manufacturing Organizations (CMOs).

This report scrutinizes the latest business conditions, encompasses a thorough analysis of new outsourcing contracts, assesses opportunities and threats, and highlights recent mergers, acquisitions, and financing activities within the CMO sector. Facility-level updates, including site openings, closures, Good Manufacturing Practice (GMP) inspections, and technological investments, are also featured.

Scope

• CMO executives and strategic decision-makers: Enhance comprehension of the CMO landscape to inform strategic planning.
• Sourcing and procurement executives in bio/pharmaceutical companies: Gain insights for selecting and managing supply base components.
• Investors, advisors, and consultants: Acquire a deeper understanding of the CMO market to identify potential investment opportunities.

Reasons to Buy

• Gain insights into current trends and formulate proactive strategies to address challenges while capitalizing on emerging trends within pharmaceutical manufacturing.
• Uncover the latest opportunities and threats in contract manufacturing, informed by clinical trials and regulatory decisions.
• Review M&A and financing activities in the manufacturing arena for the past quarter.
• Identify recent contract service agreements that could impact strategic decisions.
• Enhance competitive intelligence through detailed inspection results and facility investment reports.
• Preempt disruptions by staying informed on supply chain challenges and new regulatory developments.

Key Topics Covered:

1 Industry Trends

1.1 US healthcare agency cuts: impacts on drug approvals and supply chain

1.2 WuXi AppTec sells UK-US units, but annual results show foreign contracts continue despite China tensions

1.3 Trump tariffs drive pharma manufacturing to US but risk inflation and disruption

1.4 Semaglutide shortage ends as FDA sets deadline for compounders

1.5 Mandatory drug stock monitoring empowers EU to tackle shortages

1.6 Is space really the next frontier for medical manufacturing?

1.7 Regulatory trends in brief

2 Industry Analysis

2.1 Contract service agreements

2.2 Contract manufacturing - opportunities and threats

2.3 Quarterly mergers, acquisitions, and financing - Q1 2025

3 Value Chain

3.1 Compounding

3.2 API biologics - protein and peptide

3.3 API biologics - cell, gene, vaccine, and virus

3.4 Commercial dose manufacturing and packaging

3.5 Clinical dose manufacturing and packaging

3.6 Analytical services

4 About the Analyst

A selection of companies mentioned in this report includes, but is not limited to:

• FDA
• CDC
• NIH
• ARPA-H
• Verve Therapeutics
• WuXi AppTec
• Altaris
• NAMSA
• Eli Lilly
• Pfizer
• Merck & Co.
• Novo Nordisk
• Teva Pharmaceuticals
• Techshot
• Virtual Incision
• Auxilium
• BiologIC Technologies
• SpaceX
• CEM Analytical Services
• Almac Group
• Catalent Inc
• Celonic AG
• Cenexi SAS
• Corden Pharma International GmbH
• Kymos Pharma Services SL
• MIAS Pharma Ltd
• Midas Pharma GmbH
• Northern RNA Inc
• NUVISAN Pharma Holding GmbH
• Renaissance Lakewood LLC
• Roslin Cell Therapies Ltd
• Rottendorf Pharma GmbH
• AbbVie Inc
• AGC Biologics Inc
• Ajinomoto Bio-Pharma Services
• Boehringer Ingelheim Pharma GmbH & Co KG
• BSP Pharmaceuticals SpA
• Charles River Laboratories International Inc
• Curia Global Inc
• Delpharm SAS
• Dottikon Exclusive Synthesis AG
• Fareva SA
• Farmhispania SA
• Forge Biologics Inc
• Hikma Pharmaceuticals Plc
• Hubei Haosun Pharmaceutical Co Ltd
• Lonza Biologics Inc
• Lonza Group Ltd
• MIAS Pharma Ltd
• NorthX Biologics Matfors AB
• Novo Nordisk AS
• Organon & Co
• Patheon France SAS
• Patheon Italia SpA
• Patheon NV
• Patheon Puerto Rico Inc
• PCI Pharma Services
• Piramal Pharma Solutions Inc
• Samsung Biologics Co Ltd
• ScinoPharm Taiwan Ltd
• Sharp Packaging Services
• Simtra BioPharma Solutions
• Vetter Pharma-Fertigung GmbH & Co KG
• Vistin Pharma AS
• WuXi AppTec Co Ltd
• WuXi Biologics Cayman Inc
• Zhejiang Raybow Pharmaceutical Co Ltd
• ProRx LLC
• Axplora Group GmbH
• Bionova Scientific Inc
• Cerbios Pharma SA
• C3i Center Inc
• NecstGen BV
• Adragos Pharma GmbH
• Aenova Holding GmbH
• Biomay AG
• Celltrion Inc
• Guju Pharm Co Ltd
• Halo Pharma Inc
• Losan Pharma GmbH
• Novel Laboratories Inc
• Selkirk Pharma Inc
• CEM Analytical Services Ltd
• Improved Pharma LLC
• Nelson Laboratories LLC
• SK Pharmteco Inc

For more information about this report visit https://www.researchandmarkets.com/r/i4jarx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520621233/en/